Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 121, Issue 2, Pages 117-124
Publisher
Springer Science and Business Media LLC
Online
2019-06-11
DOI
10.1038/s41416-019-0488-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice
- (2018) Edoardo Giovanni Giannini et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
- (2018) Haider H. Samawi et al. Cancer Medicine
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis
- (2017) Richard S. Finn et al. HEPATOLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
- (2016) H. K. Sanoff et al. ONCOLOGIST
- Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials
- (2015) Yu-Yun Shao et al. ONCOLOGY
- Treating advanced hepatocellular carcinoma: How to get out of first gear
- (2014) James J. Harding et al. CANCER
- Sa1701 Cytotoxic T Lymphocyte Antigen-4 (Ctla-4) Signaling Effectively Retains Regulatory T Cells (Treg) to Alleviate Liver Injury of Patients With Acute-on-Chronic Hepatitis B (Achb)
- (2014) Jing Li et al. GASTROENTEROLOGY
- Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study
- (2014) Sangheun Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- External validation of a Cox prognostic model: principles and methods
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models
- (2011) Kyung Kee Baek et al. ONCOLOGY
- Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope
- (2008) Robin K. Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started